All In Biotech

Drug Trial Radar · NCT05333861

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Last checked: Nov 19, 2026Latest source record: Apr 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,150

Planned (sponsor's estimate)

Start

May 1, 2022

Primary completion

May 1, 2026

Study completion May 1, 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Hengrui Pharmaceutical Co., Ltd.
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA

Conditions

  • Primary Immune Thrombocytopenia
  • Aplastic Anemia

Interventions

  • hetrombopagDrug

    According to prescription

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Data will be collected for all routine visits completed during the study period no more than 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.